Premium
Photodynamic therapy for symptomatic high risk choroidal melanocytic lesions
Author(s) -
AMSELEM L,
GARCíAARUMí J,
BADAL J,
GüNDüZ K,
ADAN A,
ZAPATA MA,
VALLDEPERAS X,
CORCOSTEGUI B,
HUSTE F
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.4161.x
Subject(s) - medicine , photodynamic therapy , serous fluid , lesion , visual acuity , ophthalmology , retrospective cohort study , surgery , pathology , organic chemistry , chemistry
Purpose To evaluate the role of photodynamic therapy (PDT) for symptomatic high risk choroidal melanocytic (HRCM) lesions with subretinal fluid extending to the fovea. Methods Retrospective review of the medical records of all patients who underwent PDT for a HRCM lesion. Results Seventeen patients were included in the study. The mean initial visual acuity was 20/80 (range CF‐20/20). The mean initial tumor thickness was 1.23 mm (range 0.66‐1.93). All tumors presented at least 2 risk factors for growing. The mean number of PDT sessions was 1.41 (range 1‐3). The mean final visual acuity improved to 20/60 (range CF‐ 20/20). Subretinal fluid was reduced in all (100%) eyes and had completely disappeared in 9 (53%) eyes after PDT. The mean final tumor thickness increased to 1.24 mm (range 0.66 to 2.01) at a mean follow‐up of 22.47 months (range 6‐60). Tumor thickness increased in 3 (18%) eyes, remained unchanged in 13 (76%) eyes, and 1 (6%) lesion shrank down to a flat chorioretinal scar. Conclusion PDT prevents vision loss with improvement of choroidal leakage in HRCM lesions with serous macular detachment, but doesn´t allow a good local tumor control. Longer follow‐up is required to determine its value in these patients.